Celularity

Celularity News

News

0

Ticker

CELU

ISIN

US1511902041

Chiffre d'affaires Résultat net P/E P/S EBIT Dividende Achats de membres du conseil Actions Capitalisation boursière Endettement Passifs Capitaux propres AAQS Effectifs ROE ROA ROCE News Documents

Actualités Eulerpool Celularity

Actualités de l'action Celularity

Celularity est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Celularity.

Communiqués de presse relatifs à l'action Celularity

Celularity publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

Celularity News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Celularity (CELU, ISIN : US1511902041). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Celularity.

Celularity Action

Celularity Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/.